摘要
目的为临床选择糖尿病周围神经病变(DPN)治疗用补气活血类中成药提供参考。方法参考《医疗机构中成药遴选专家共识(第一版)》,结合临床实际,制订药物卫生技术评估细则,参考药品说明书、临床指南和文献,对4种中成药的安全性、有效性、经济性、适宜性、创新性、可及性、传承性进行评分,并计算总分。结果通心络胶囊、木丹颗粒、糖脉康颗粒、芪蛭降糖胶囊的评分分别为74.5分、72分、64.5分、57分。结论临床在选择治疗DPN的补气活血类中成药时,相对于糖脉康颗粒、芪蛭降糖胶囊,建议优先使用木丹颗粒、通心络胶囊。
Objective To provide a reference for clinical selection of tonifying-Qi and promoting-blood-circulation Chinese patent medicines in the treatment of diabetic peripheral neuropathy(DPN).Methods The details for drug health technology assessment were formulated based on the Consensus of Experts in the Selection of Chinese Patent Medicine in Medical Institutions(First Edition)and clinical practice.The safety,effectiveness,economy,suitability,innovativeness,accessibility and inheritance of four Chinese patent medicines were scored based on the drug instructions,clinical guidelines and literature,and the total score was calculated.Results The scores of Tongxinluo Capsules,Mudan Granules,Tangmaikang Granules and Qizhi Jiangtang Capsules were 74.5,72,64.5,57 points respectively.Conclusion In the selection of tonifying-Qi and promoting-blood-circulation Chinese patent medicines in the treatment of DPN,Mudan Granules and Tongxinluo Capsules are preferred to Tangmaikang Granules and Qizhi Jiangtang Capsules.
作者
王玉娟
郝晓飞
范顺心
田虹利
程杰
WANG Yujuan;HAO Xiaofei;FAN Shunxin;TIAN Hongli;CHENG Jie(Hebei Hospital of Traditional Chinese Medicine,Shijiazhuang,Hebei,China 050000;Hebei Industrial Technology Institute for Traditional Chinese Medicine Preparation,Shijiazhuang,Hebei,China 050000)
出处
《中国药业》
CAS
2024年第6期109-114,共6页
China Pharmaceuticals
基金
河北省中医药管理局科研计划项目[2022027]。
关键词
医院卫生技术评估
药品遴选
糖尿病周围神经病变
中成药
补气活血
hospital-based health technology assessment
drug selection
diabetic peripheral neuropathy
Chinese patent medicine
tonifying Qi and promoting blood circulation
